DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Preladenant is an investigational drug.
There have been 13 clinical trials for Preladenant. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Parkinson Disease, Dyskinesias, and Movement Disorders. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Oregon Health and Science University, and [disabled in preview].
Recent Clinical Trials for Preladenant
|Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)||Merck Sharp & Dohme Corp.||Phase 1|
|A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)||Merck Sharp & Dohme Corp.||Phase 1|
|A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)||Merck Sharp & Dohme Corp.||Phase 1|